| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
PEGs
As a PEG-based PROTAC linker, CH2COOH-PEG6-CH2COOH does not have a specific biological target itself but serves as a structural component in PROTAC molecules. The PEG category of linkers is used to connect the E3 ubiquitin ligase ligand to the target protein ligand in PROTAC design. In this context, one ligand binds to an E3 ubiquitin ligase and the other binds to the target protein; these two ligands are joined by the linker to form PROTACs. The intracellular ubiquitin-proteasome system is then utilized by PROTACs to specifically destroy target proteins. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
CH2COOH-PEG6-CH2COOH functions as a linker component in in vitro PROTAC synthesis and bioconjugation applications. The two carboxylic acid groups allow for efficient conjugation to primary amines on target ligands and E3 ligase ligands via amide bond formation. The PEG6 spacer provides excellent water solubility and molecular flexibility, which is critical for the formation of the ternary complex between the target protein, PROTAC, and E3 ligase. In vitro studies typically involve conjugation of this linker to various ligands to evaluate its effectiveness in facilitating protein degradation. |
| ln Vivo |
In vivo activity data for CH2COOH-PEG6-CH2COOH as a standalone compound are not reported, as it is utilized as a synthetic linker rather than as a therapeutic agent. The in vivo efficacy of PROTAC molecules incorporating this PEG6 linker would depend on the specific target protein ligand and the overall pharmacokinetic properties of the complete PROTAC construct. As a hydrophilic PEG-based linker, it may contribute to improved pharmacokinetic properties of conjugated molecules by enhancing solubility and reducing immunogenicity.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for CH2COOH-PEG6-CH2COOH typically involve conjugation studies rather than direct binding measurements. The carboxylic acid groups can be activated for conjugation to primary amines, and conjugation efficiency can be assessed by techniques such as NMR spectroscopy, mass spectrometry, or HPLC. Surface plasmon resonance (SPR) may be employed to evaluate the binding of PROTAC molecules containing this linker to their targets. The PEG6 spacer minimizes steric hindrance, allowing efficient conjugation and maintaining the biological activity of the conjugated molecule.
|
| Cell Assay |
In vitro cell-based assays using CH2COOH-PEG6-CH2COOH typically involve its incorporation into PROTAC molecules, followed by evaluation in cell culture systems. Cells are treated with PROTACs containing this PEG6 linker, and target protein degradation is measured by Western blotting or immunofluorescence. Dose-response experiments are performed to determine optimal concentrations for degradation studies. The PEG6 chain provides excellent water solubility, facilitating compound handling and delivery in cell culture media.
|
| Animal Protocol |
In vivo animal studies using CH2COOH-PEG6-CH2COOH are conducted as part of the evaluation of complete PROTAC molecules that incorporate this PEG6 linker. Typical protocols involve administering PROTAC constructs to animal models, followed by assessment of pharmacokinetics, biodistribution, or efficacy. The PEG6 spacer is expected to improve the pharmacokinetic profile by increasing hydrophilicity and reducing protein adsorption. Dosing regimens vary depending on the specific construct being evaluated and the disease model under study.
|
| ADME/Pharmacokinetics |
As a linker rather than a therapeutic drug, comprehensive pharmacokinetic data for CH2COOH-PEG6-CH2COOH alone are not available. The compound has a molecular formula of C16H30O11 and a molecular weight of 398.40. It has a purity of ≥95%. The compound is also known as 3,6,9,12,15,18,21-heptaoxatricosanedioic acid. When incorporated into PROTAC molecules, the PEG6 linker contributes to the overall physicochemical properties of the complete construct.
|
| Toxicity/Toxicokinetics |
The toxicity profile of CH2COOH-PEG6-CH2COOH as an individual compound is not extensively characterized, as it is primarily used as a research reagent and synthetic linker. The compound is intended for research use only and is not approved for therapeutic use in humans. PEG-based compounds are generally considered to have low toxicity and good biocompatibility. Standard laboratory safety practices, including the use of personal protective equipment, are recommended.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
|
| Additional Infomation |
CH2COOH-PEG6-CH2COOH (CAS 83824-29-7) has a molecular formula of C16H30O11 and a molecular weight of 398.40. It has a purity of ≥95%. It is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. The compound is also known as 3,6,9,12,15,18,21-heptaoxatricosanedioic acid. It belongs to the PEG category of PROTAC linkers.
|
| Molecular Formula |
C16H30O11
|
|---|---|
| Molecular Weight |
398.40
|
| Exact Mass |
398.179
|
| CAS # |
83824-29-7
|
| PubChem CID |
10739619
|
| Appearance |
Light yellow to yellow viscous liquid
|
| LogP |
-1.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
27
|
| Complexity |
319
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(COCCOCCOCC(=O)O)OCCOCCOCCOCC(=O)O
|
| InChi Key |
RFYAZDYSJVSCDL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H30O11/c17-15(18)13-26-11-9-24-7-5-22-3-1-21-2-4-23-6-8-25-10-12-27-14-16(19)20/h1-14H2,(H,17,18)(H,19,20)
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-(carboxymethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5100 mL | 12.5502 mL | 25.1004 mL | |
| 5 mM | 0.5020 mL | 2.5100 mL | 5.0201 mL | |
| 10 mM | 0.2510 mL | 1.2550 mL | 2.5100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
